Although DS is widely accepted as a method for expanding LT indication in HCC, unresolved issues remain, such as establishing the limits on tumor burden and AFP levels for DS candidacy, as well as defining the criteria for successful DS in terms of the extent and duration of tumor response. Here, AFP is linked to hepatocellular carcinoma.